The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

S Cheng, N Prieto-Dominguez, S Yang… - Prostate cancer and …, 2020 - nature.com
Background After long-term androgen deprivation therapy, 25–30% prostate cancer (PCa)
acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of YAP1, a key …
被引用次数：45 相关文章

The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

S Cheng, N Prieto-Dominguez… - Prostate cancer …, 2020 - pubmed.ncbi.nlm.nih.gov
Background After long-term androgen deprivation therapy, 25-30% prostate cancer (PCa)
acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of YAP1, a key …

The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.

S Cheng, N Prieto-Dominguez, S Yang… - Prostate Cancer and …, 2020 - go.gale.com
Background After long-term androgen deprivation therapy, 25-30% prostate cancer (PCa)
acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of YAP1, a key …
[PDF] researchgate.net

[PDF][PDF] The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

S Cheng, N Prieto-Dominguez, S Yang, ZM Connelly… - researchgate.net
ABSTRACT BACKGROUND After long-term androgen deprivation therapy, 25-30% prostate
cancer (PCa) acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of …

[引用][C] The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

S Cheng, N Prieto-Dominguez, S Yang… - Prostate Cancer and …, 2020 - cir.nii.ac.jp
The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced
in neuroendocrine prostate cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.

S Cheng, N Prieto-Dominguez, S Yang… - Prostate Cancer and …, 2020 - europepmc.org
Background After long-term androgen deprivation therapy, 25-30% prostate cancer (PCa)
acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of YAP1, a key …

The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

S Cheng, N Prieto-Dominguez, S Yang, ZM Connelly… - bioRxiv, 2019 - biorxiv.org
ABSTRACT BACKGROUND After long-term androgen deprivation therapy, 25-30% prostate
cancer (PCa) acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of …
[PDF] archive.org

[PDF][PDF] The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

S Cheng, N Prieto-Dominguez, S Yang, ZM Connelly… - scholar.archive.org
ABSTRACT BACKGROUND After long-term androgen deprivation therapy, 25-30% prostate
cancer (PCa) acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of …
[PDF] academia.edu

[PDF][PDF] The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

S Cheng, N Prieto-Dominguez, S Yang, ZM Connelly… - academia.edu
ABSTRACT BACKGROUND After long-term androgen deprivation therapy, 25-30% prostate
cancer (PCa) acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of …
[HTML] nih.gov

[HTML][HTML] The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

S Cheng, N Prieto-Dominguez, S Yang… - Prostate cancer and …, 2020 - ncbi.nlm.nih.gov
BACKGROUND After long-term androgen deprivation therapy, 25–30% prostate cancer
(PCa) acquires an aggressive neuroendocrine (NE) phenotype. Dysregulation of YAP1, a …